Next-generation CRISPR screens to fast-forward drug discovery

Our technology platform

At Myllia, we perform functional genomics at scale in advanced cellular models to map the impact of thousands of genetic perturbations at single-cell resolution – a new paradigm to nominate the best possible targets for your drug discovery campaign. Our technology platform enables tailor-made CRISPR screens:

Applications for drug discovery

Pooled CRISPR screens accelerate drug target discovery across many therapeutic areas and help unravel gene regulatory networks in cancer cells and primary human T cells. We utilize CRISPR KO, CRISPRi and CRISPRa technologies combined with multiple high-throughput read-outs for various applications:

Blue target icon symbolizing the CRISPR drug screen for target identification

Drug target identification and validation

Screen in blue with an ascending graph representing the CRISPR drug screen analysis.

Mode of action (MoA) analysis

DNA icon in blue to illustrate the identification of disease-associated gene functions.

Identification of disease-associated gene function

Network icon in blue to illustrate the genetic perturbation screening of primary T cell subsets.

Genetic screening for primary T cell phenotypes

Genetic perturbation screens at single-cell resolution revolutionize the way we identify novel drug targets and gene regulatory networks involved in oncology and autoimmune disease.